Top

The Journal of Headache and Pain

Published in:

Open Access 01-12-2016 | Research article

Network meta-analysis of migraine disorder treatment by NSAIDs and triptans

Authors: Haiyang Xu, Wei Han, Jinghua Wang, Mingxian Li

Published in: The Journal of Headache and Pain | Issue 1/2015

Abstract

Background

Migraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans.

Methods

We conducted systematic searches in database PubMed and Embase. Treatment effectiveness was compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area (SUCRA) was created to rank those interventions.

Results

Eletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan.

Conclusion

This study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.

Available only for authorised users

Stewart WF, Lipton RB, Celentano DD, Reed ML (1992) Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 267(1):64–69PubMedCrossRef

Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M (2001) Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 41(7):646–657PubMedCrossRef

Gobel H, Petersen-Braun M, Soyka D (1994) The epidemiology of headache in Germany: a nationwide survey of a representative sample on the basis of the headache classification of the International Headache Society. Cephalalgia 14(2):97–106PubMedCrossRef

Henry P, Michel P, Brochet B, Dartigues JF, Tison S, Salamon R (1992) A nationwide survey of migraine in France: prevalence and clinical features in adults. GRIM. Cephalalgia 12(4):229–237, discussion 186PubMedCrossRef

Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A (2016) Recent advances in migraine therapy. Springerplus 5:637PubMedPubMedCentralCrossRef

Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E (2012) Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 78(17):1337–1345PubMedPubMedCentralCrossRef

Evers S, Afra J, Frese A, Goadsby PJ, Linde M, May A et al (2009) EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 16(9):968–981PubMedCrossRef

Marmura MJ, Silberstein SD, Schwedt TJ (2015) The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache 55(1):3–20PubMedCrossRef

Pringsheim T, Davenport WJ, Marmura MJ, Schwedt TJ, Silberstein S (2016) How to apply the AHS evidence assessment of the acute treatment of migraine in adults to your patient with migraine. Headache 56(7):1194–1200PubMedCrossRef

10.

Diamond ML, Hettiarachchi J, Hilliard B, Sands G, Nett R (2004) Effectiveness of eletriptan in acute migraine: primary care for Excedrin nonresponders. Headache 44(3):209–216PubMedCrossRef

11.

Pascual J, Cabarrocas X (2002) Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better. Headache 42(1):28–31PubMedCrossRef

12.

Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2004) Almotriptan improves response rates when treatment is within 1 hour of migraine onset. Headache 44(4):318–322PubMedCrossRef

13.

Burstein R, Collins B, Jakubowski M (2004) Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 55(1):19–26PubMedCrossRef

14.

Linde M, Mellberg A, Dahlof C (2006) Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack. Cephalalgia 26(2):113–121PubMedCrossRef

15.

(1999) Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia 19(4):232–240

16.

Ahrens SP, Farmer MV, Williams DL, Willoughby E, Jiang K, Block GA et al (1999) Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 19(5):525–530PubMedCrossRef

17.

Barbanti P, Carpay JA, Kwong WJ, Ahmad F, Boswell D (2004) Effects of a fast disintegrating/rapid release oral formulation of sumatriptan on functional ability in patients with migraine. Curr Med Res Opin 20(12):2021–2029PubMedCrossRef

18.

Bomhof M, Paz J, Legg N, Allen C, Vandormael K, Patel K (1999) Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 42(3):173–179PubMedCrossRef

19.

Bousser MG, D’Allens H, Richard A (1993) Efficacy of subcutaneous sumatriptan in the acute treatment of early-morning migraine: a placebo-controlled trial. Early-Morning Migraine Sumatriptan Study Group. J Intern Med 234(2):211–216PubMedCrossRef

20.

Brandes JL, Kudrow D, Stark SR, O’Carroll CP, Adelman JU, O’Donnell FJ et al (2007) Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA 297(13):1443–1454PubMedCrossRef

21.

Bussone G, Manzoni GC, Cortelli P, Roncolato M, Fabbri L, Benassuti C (2000) Efficacy and tolerability of sumatriptan in the treatment of multiple migraine attacks. Neurol Sci 21(5):272–278PubMedCrossRef

22.

Cady RC, Ryan R, Jhingran P, O’Quinn S, Pait DG (1998) Sumatriptan injection reduces productivity loss during a migraine attack: results of a double-blind, placebo-controlled trial. Arch Intern Med 158(9):1013–1018PubMedCrossRef

23.

Carleton SC, Shesser RF, Pietrzak MP, Chudnofsky CR, Starkman S, Morris DL et al (1998) Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 32(2):129–138PubMedCrossRef

24.

Charlesworth BR, Dowson AJ, Purdy A, Becker WJ, Boes-Hansen S, Farkkila M (2003) Speed of onset and efficacy of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled, dose-ranging study versus zolmitriptan tablet. CNS Drugs 17(9):653–667PubMedCrossRef

25.

Codispoti JR, Prior MJ, Fu M, Harte CM, Nelson EB (2001) Efficacy of nonprescription doses of ibuprofen for treating migraine headache. A randomized controlled trial. Headache 41(7):665–679PubMedCrossRef

26.

Dahlof C, Diener HC, Goadsby PJ, Massiou H, Olesen J, Schoenen J et al (1998) Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 5(6):535–543PubMedCrossRef

27.

Dahlof C, Hogenhuis L, Olesen J, Petit H, Ribbat J, Schoenen J et al (1998) Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study. Eur J Neurol 5(5):469–477PubMedCrossRef

28.

Diamond S, Elkind A, Jackson RT, Ryan R, DeBussey S, Asgharnejad M (1998) Multiple-attack efficacy and tolerability of sumatriptan nasal spray in the treatment of migraine. Arch Fam Med 7(3):234–240PubMedCrossRef

29.

Diener HC (1999) Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Cephalalgia 19(6):581–588, discussion 542PubMedCrossRef

30.

Diener HC, Bussone G, De Liano H, Eikermann A, Englert R, Floeter T et al (2004) Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 24(11):947–954PubMedCrossRef

31.

Diener HC, Eikermann A, Gessner U, Gobel H, Haag G, Lange R et al (2004) Efficacy of 1,000 mg effervescent acetylsalicylic acid and sumatriptan in treating associated migraine symptoms. Eur Neurol 52(1):50–56PubMedCrossRef

32.

Diener HC, Gendolla A, Gebert I, Beneke M (2005) Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial. Eur Neurol 53(Suppl 1):41–48PubMedCrossRef

33.

Diener HC, Jansen JP, Reches A, Pascual J, Pitei D, Steiner TJ (2002) Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol 47(2):99–107PubMedCrossRef

34.

Diener HC, Montagna P, Gács G, Lyczak P, Schumann G, Zöller B et al (2006) Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 26(5):537–547PubMedCrossRef

35.

Djupesland PG, Docekal P (2010) Intranasal sumatriptan powder delivered by a novel breath-actuated bi-directional device for the acute treatment of migraine: a randomised, placebo-controlled study. Cephalalgia 30(8):933–942PubMed

36.

Dodick D, Brandes J, Elkind A, Mathew N, Rodichok L (2005) Speed of onset, efficacy and tolerability of zolmitriptan nasal spray in the acute treatment of migraine: a randomised, double-blind, placebo-controlled study. CNS Drugs 19(2):125–136PubMedCrossRef

37.

Dodick DW (2002) Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 42(1):21–27PubMedCrossRef

38.

Dowson A, Ball K, Haworth D (2000) Comparison of a fixed combination of domperidone and paracetamol (Domperamol) with sumatriptan 50 mg in moderate to severe migraine: a randomised UK primary care study. Curr Med Res Opin 16(3):190–197PubMedCrossRef

39.

Dowson AJ, MacGregor EA, Purdy RA, Becker WJ, Green J, Levy SL (2002) Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 22(2):101–106PubMedCrossRef

40.

Dowson AJ, Massiou H, Lainez JM, Cabarrocas X (2002) Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 22(6):453–461PubMedCrossRef

41.

Freitag F, Diamond M, Diamond S, Janssen I, Rodgers A, Skobieranda F (2008) Efficacy and tolerability of coadministration of rizatriptan and acetaminophen vs rizatriptan or acetaminophen alone for acute migraine treatment. Headache 48(6):921–930PubMedCrossRef

42.

Gallagher RM, Dennish G, Spierings EL, Chitra R (2000) A comparative trial of zolmitriptan and sumatriptan for the acute oral treatment of migraine. Headache 40(2):119–128PubMedCrossRef

43.

Gawel M, Aschoff J, May A, Charlesworth BR (2005) Zolmitriptan 5 mg nasal spray: efficacy and onset of action in the acute treatment of migraine--results from phase 1 of the REALIZE Study. Headache 45(1):7–16PubMedCrossRef

44.

Geraud G, Compagnon A, Rossi A (2002) Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 47(2):88–98PubMedCrossRef

45.

Geraud G, Olesen J, Pfaffenrath V, Tfelt-Hansen P, Zupping R, Diener HC et al (2000) Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 20(1):30–38PubMedCrossRef

46.

Goadsby PJ, Massiou H, Pascual J, Diener HC, Dahlof CG, Mateos V et al (2007) Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 115(1):34–40PubMedCrossRef

47.

Gobel H, Winter P, Boswell D, Crisp A, Becker W, Hauge T et al (2000) Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Naratriptan International Recurrence Study Group. Clin Ther 22(8):981–989PubMedCrossRef

48.

Goldstein J, Ryan R, Jiang K, Getson A, Norman B, Block GA et al (1998) Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group. Headache 38(10):737–747PubMedCrossRef

49.

Goldstein J, Silberstein SD, Saper JR, Elkind AH, Smith TR, Gallagher RM et al (2005) Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial. Headache 45(8):973–982PubMedCrossRef

50.

Goldstein J, Silberstein SD, Saper JR, Ryan RE Jr, Lipton RB (2006) Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache 46(3):444–453PubMedCrossRef

51.

Gross ML, Kay J, Turner AM, Hallett K, Cleal AL, Hassani H (1994) Sumatriptan in acute migraine using a novel cartridge system self-injector. United Kingdom Study Group. Headache 34(10):559–563PubMedCrossRef

52.

Gruffyd-Jones K, Kies B, Middleton A, Mulder LJ, Rosjo O, Millson DS (2001) Zolmitriptan versus sumatriptan for the acute oral treatment of migraine: a randomized, double-blind, international study. Eur J Neurol 8(3):237–245PubMedCrossRef

53.

Havanka H, Dahlof C, Pop PH, Diener HC, Winter P, Whitehouse H et al (2000) Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clin Ther 22(8):970–980PubMedCrossRef

54.

Henry P, d’Allens H (1993) Subcutaneous sumatriptan in the acute treatment of migraine in patients using dihydroergotamine as prophylaxis. French Migraine Network Bordeaux-Lyon-Grenoble. Headache 33(8):432–435PubMedCrossRef

55.

Jelinski SE, Becker WJ, Christie SN, Ahmad FE, Pryse-Phillips W, Simpson SD (2006) Pain free efficacy of sumatriptan in the early treatment of migraine. Can J Neurol Sci 33(1):73–79PubMedCrossRef

56.

Kellstein DE, Lipton RB, Geetha R, Koronkiewicz K, Evans FT, Stewart WF et al (2000) Evaluation of a novel solubilized formulation of ibuprofen in the treatment of migraine headache: a randomized, double-blind, placebo-controlled, dose-ranging study. Cephalalgia 20(4):233–243PubMedCrossRef

57.

Klapper J, Lucas C, Rosjo O, Charlesworth B (2004) Benefits of treating highly disabled migraine patients with zolmitriptan while pain is mild. Cephalalgia 24(11):918–924PubMedCrossRef

58.

Kolodny A, Polis A, Battisti WP, Johnson-Pratt L, Skobieranda F (2004) Comparison of rizatriptan 5 mg and 10 mg tablets and sumatriptan 25 mg and 50 mg tablets. Cephalalgia 24(7):540–546PubMedCrossRef

59.

Lange R, Schwarz JA, Hohn M (2000) Acetylsalicylic acid effervescent 1000 mg (Aspirin) in acute migraine attacks; a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 20(7):663–667PubMed

60.

Le Jeunne C, Gomez JP, Pradalier A, Titus i Albareda F, Joffroy A, Liano H et al (1999) Comparative efficacy and safety of calcium carbasalate plus metoclopramide versus ergotamine tartrate plus caffeine in the treatment of acute migraine attacks. Eur Neurol 41(1):37–43PubMedCrossRef

61.

Lewis DW, Kellstein D, Dahl G, Burke B, Frank LM, Toor S et al (2002) Children’s ibuprofen suspension for the acute treatment of pediatric migraine. Headache 42(8):780–786PubMedCrossRef

62.

Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M (2000) Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, population-based study. Arch Intern Med 160(22):3486–3492PubMedCrossRef

63.

Lipton RB, Goldstein J, Baggish JS, Yataco AR, Sorrentino JV, Quiring JN (2005) Aspirin is efficacious for the treatment of acute migraine. Headache 45(4):283–292PubMedCrossRef

64.

Lipton RB, Grosberg B, Singer RP, Pearlman SH, Sorrentino JV, Quiring JN et al (2010) Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 30(11):1336–1345PubMedCrossRef

65.

Lipton RB, Stewart WF, Cady R, Hall C, O’Quinn S, Kuhn T et al (2000) Sumatriptan for the range of headaches in migraine sufferers: results of the spectrum study. Headache 40(10):783–791PubMedCrossRef

66.

Loder E, Freitag FG, Adelman J, Pearlmand S, Abu-Shakra S (2005) Pain-free rates with zolmitriptan 2.5 mg ODT in the acute treatment of migraine: results of a large double-blind placebo- controlled trial. Curr Med Res Opin 21(3):381–389PubMedCrossRef

67.

MacGregor EA, Dowson A, Davies PT (2002) Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache 42(4):249–255PubMedCrossRef

68.

Mannix LK, Loder E, Nett R, Mueller L, Rodgers A, Hustad CM et al (2007) Rizatriptan for the acute treatment of ICHD-II proposed menstrual migraine: two prospective, randomized, placebo-controlled, double-blind studies. Cephalalgia 27(5):414–421PubMedCrossRef

69.

Mannix LK, Martin VT, Cady RK, Diamond ML, Lener SE, White JD et al (2009) Combination treatment for menstrual migraine and dysmenorrhea using sumatriptan-naproxen: two randomized controlled trials. Obstet Gynecol 114(1):106–113PubMedCrossRef

70.

Mathew NT, Finlayson G, Smith TR, Cady RK, Adelman J, Mao L et al (2007) Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study). Headache 47(2):189–198PubMedCrossRef

71.

Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR (2003) Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 43(3):214–222PubMedCrossRef

72.

Misra UK, Jose M, Kalita J (2004) Rofecoxib versus ibuprofen for acute treatment of migrainne: a randomised placebo controlled trial. Postgrad Med J 80(950):720–723PubMedPubMedCentralCrossRef

73.

Misra UK, Kalita J, Yadav RK (2007) Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial. J Headache Pain 8(3):175–179PubMedPubMedCentralCrossRef

74.

Myllyla VV, Havanka H, Herrala L, Kangasniemi P, Rautakorpi I, Turkka J et al (1998) Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 38(3):201–207PubMedCrossRef

75.

Nappi G, Sicuteri F, Byrne M, Roncolato M, Zerbini O (1994) Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 241(3):138–144PubMedCrossRef

76.

Pascual J, Falk RM, Piessens F, Prusinski A, Docekal P, Robert M et al (2000) Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 20(6):588–596PubMedCrossRef

77.

Pascual J, Vega P, Diener HC, Allen C, Vrijens F, Patel K (2000) Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Rizatriptan-Zolmitriptan Study Group. Cephalalgia 20(5):455–461PubMedCrossRef

78.

Peikert A, Becker WJ, Ashford EA, Dahlof C, Hassani H, Salonen RJ (1999) Sumatriptan nasal spray: a dose-ranging study in the acute treatment of migraine. Eur J Neurol 6(1):43–49PubMedCrossRef

79.

Peroutka SJ, Lyon JA, Swarbrick J, Lipton RB, Kolodner K, Goldstein J (2004) Efficacy of diclofenac sodium softgel 100 mg with or without caffeine 100 mg in migraine without aura: a randomized, double-blind, crossover study. Headache 44(2):136–141PubMedCrossRef

80.

Pfaffenrath V, Cunin G, Sjonell G, Prendergast S (1998) Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 38(3):184–190PubMedCrossRef

81.

Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J (2006) Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents. Headache 46(1):101–109PubMedCrossRef

82.

Ryan RE Jr, Diamond S, Giammarco RAM, Aurora SK, Reed RC, Fletcher PE (2000) Efficacy of Zolmitriptan at early time-points for the acute treatment of migraine and treatment of recurrence: a randomised, placebo-controlled trial. CNS Drugs 13(3):215–226CrossRef

83.

Sakai F, Iwata M, Tashiro K, Itoyama Y, Tsuji S, Fukuuchi Y et al (2002) Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose–response study. Cephalalgia 22(5):376–383PubMedCrossRef

84.

Salonen R, Ashford E, Dahlof C, Dawson R, Gilhus NE, Luben V et al (1994) Intranasal sumatriptan for the acute treatment of migraine. International Intranasal Sumatriptan Study Group. J Neurol 241(8):463–469PubMedCrossRef

85.

Scherl ER, Wilson JF (1995) Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 35(5):256–259PubMedCrossRef

86.

Schulman EA, Cady RK, Henry D, Batenhorst AS, Putnam DG, Watson CB et al (2000) Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 75(8):782–789PubMedCrossRef

87.

Schulman EA, Dermott KF (2003) Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 43(7):729–733PubMedCrossRef

88.

Sheftell FD, Dahlof CG, Brandes JL, Agosti R, Jones MW, Barrett PS (2005) Two replicate randomized, double-blind, placebo-controlled trials of the time to onset of pain relief in the acute treatment of migraine with a fast-disintegrating/rapid-release formulation of sumatriptan tablets. Clin Ther 27(4):407–417PubMedCrossRef

89.

Smith TR, Sunshine A, Stark SR, Littlefield DE, Spruill SE, Alexander WJ (2005) Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 45(8):983–991PubMedCrossRef

90.

Spierings EL, Gomez-Mancilla B, Grosz DE, Rowland CR, Whaley FS, Jirgens KJ (2001) Oral almotriptan vs. oral sumatriptan in the abortive treatment of migraine: a double-blind, randomized, parallel-group, optimum-dose comparison. Arch Neurol 58(6):944–950PubMedCrossRef

91.

Spierings EL, Rapoport AM, Dodick DW, Charlesworth B (2004) Acute treatment of migraine with zolmitriptan 5 mg orally disintegrating tablet. CNS Drugs 18(15):1133–1141PubMedCrossRef

92.

Steiner TJ, Diener HC, MacGregor EA, Schoenen J, Muirheads N, Sikes CR (2003) Comparative efficacy of eletriptan and zolmitriptan in the acute treatment of migraine. Cephalalgia 23(10):942–952PubMedCrossRef

93.

Teall J, Tuchman M, Cutler N, Gross M, Willoughby E, Smith B et al (1998) Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 38(4):281–287PubMedCrossRef

94.

Tepper SJ, Donnan GA, Dowson AJ, Bomhof MA, Elkind A, Meloche J et al (1999) A long-term study to maximise migraine relief with zolmitriptan. Curr Med Res Opin 15(4):254–271PubMedCrossRef

95.

Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G (1995) The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 346(8980):923–926PubMedCrossRef

96.

Tfelt-Hansen P, Teall J, Rodriguez F, Giacovazzo M, Paz J, Malbecq W et al (1998) Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group. Headache 38(10):748–755PubMedCrossRef

97.

Touchon J, Bertin L, Pilgrim AJ, Ashford E, Bes A (1996) A comparison of subcutaneous sumatriptan and dihydroergotamine nasal spray in the acute treatment of migraine. Neurology 47(2):361–365PubMedCrossRef

98.

Tullo V, Allais G, Ferrari MD, Curone M, Mea E, Omboni S et al (2010) Frovatriptan versus zolmitriptan for the acute treatment of migraine: a double-blind, randomized, multicenter, Italian study. Neurol Sci 31(Suppl 1):S51–S54PubMedCrossRef

99.

Wang SJ, Fuh JL, Wu ZA (2007) Intranasal sumatriptan study with high placebo response in Taiwanese patients with migraine. J Chin Med Assoc 70(2):39–46PubMedCrossRef

100.

Wendt J, Cady R, Singer R, Peters K, Webster C, Kori S et al (2006) A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther 28(4):517–526PubMedCrossRef

101.

Winner P, Mannix LK, Putnam DG, McNeal S, Kwong J, O’Quinn S et al (2003) Pain-free results with sumatriptan taken at the first sign of migraine pain: 2 randomized, double-blind, placebo-controlled studies. Mayo Clin Proc 78(10):1214–1222PubMedCrossRef

102.

Capi M, Curto M, Lionetto L, de Andres F, Gentile G, Negro A et al (2016) Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord 9(5):414–423PubMedPubMedCentralCrossRef

103.

Lionetto L, Casolla B, Mastropietri F, D’Alonzo L, Negro A, Simmaco M et al (2012) Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin Drug Metab Toxicol 8(8):1043–1050PubMedCrossRef

104.

Napoletano F, Lionetto L, Martelletti P (2014) Sumatriptan in clinical practice: effectiveness in migraine and the problem of psychiatric comorbidity. Expert Opin Pharmacother 15(3):303–305PubMedCrossRef

105.

Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A et al (2015) Triptans in the acute treatment of migraine: a systematic review and network meta-analysis. Headache 55(Suppl 4):221–235PubMedCrossRef

106.

Napier C, Stewart M, Melrose H, Hopkins B, McHarg A, Wallis R (1999) Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors. Eur J Pharmacol 368(2–3):259–268PubMedCrossRef

107.

Knyihar-Csillik E, Tajti J, Csillik AE, Chadaide Z, Mihaly A, Vecsei L (2000) Effects of eletriptan on the peptidergic innervation of the cerebral dura mater and trigeminal ganglion, and on the expression of c-fos and c-jun in the trigeminal complex of the rat in an experimental migraine model. Eur J Neurosci 12(11):3991–4002PubMedCrossRef

108.

Johnson DE, Rollema H, Schmidt AW, McHarg AD (2001) Serotonergic effects and extracellular brain levels of eletriptan, zolmitriptan and sumatriptan in rat brain. Eur J Pharmacol 425(3):203–210PubMedCrossRef

109.

Patrono C, Patrignani P, Garcia Rodriguez LA (2001) Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 108(1):7–13PubMedPubMedCentralCrossRef

110.

Patrono C, Baigent C (2009) Low-dose aspirin, coxibs, and other NSAIDS: a clinical mosaic emerges. Mol Interv 9(1):31–39PubMedCrossRef

111.

Goadsby PJ, Lipton RB, Ferrari MD (2002) Migraine--current understanding and treatment. N Engl J Med 346(4):257–270PubMedCrossRef

112.

Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 123(Pt 8):1703–1709PubMedCrossRef

113.

Burstein R (2001) Deconstructing migraine headache into peripheral and central sensitization. Pain 89(2–3):107–110PubMedCrossRef

114.

Loo CY, Tan HJ, Teh HS, Raymond AA (2007) Randomised, open label, controlled trial of celecoxib in the treatment of acute migraine. Singapore Med J 48(9):834–839PubMed

115.

Krymchantowski AV, Bigal ME (2004) Rizatriptan versus rizatriptan plus rofecoxib versus rizatriptan plus tolfenamic acid in the acute treatment of migraine. BMC Neurol 4:10PubMedPubMedCentralCrossRef

116.

Krymchantowski AV, Barbosa JS (2002) Rizatriptan combined with rofecoxib vs. rizatriptan for the acute treatment of migraine: an open label pilot study. Cephalalgia 22(4):309–312PubMedCrossRef

Title: Network meta-analysis of migraine disorder treatment by NSAIDs and triptans
Authors: Haiyang Xu
Wei Han
Jinghua Wang
Mingxian Li
Publication date: 01-12-2016
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/s10194-016-0703-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Network meta-analysis of migraine disorder treatment by NSAIDs and triptans

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2015

The potential impact of primary headache disorders on stroke risk

Risk of medication overuse headache across classes of treatments for acute migraine

The prevalence of primary headache disorders in Ethiopia

Headaches attributed to airplane travel: a Danish survey

Cluster headache in Greece: an observational clinical and demographic study of 302 patients

Phenotypic features of chronic migraine